Pharmather is planning to meet with the U.S. Food and Drug Administration (FDA) in hopes of reaching an agreement on the design of a future Phase 3 clinical trial testing its generic ketamine product Ketarx in individuals with Parkinson’s disease. The plans were mentioned in a company…
Parkinson’s disease patients in a clinical trial preferred Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) technology — which automatically adjusts stimulation in response to brain signals — to traditional continuous DBS therapy. The ADAPT-PD (NCT04547712) study also found that BrainSense was safe and effective, and that it…
Oncodesign Precision Medicine (OPM) joined a Michael J. Fox Foundation (MJFF) program to develop potential therapies that target the LRRK2 protein, a key contributor to some forms of Parkinson’s disease. “Our mission has always been to put patients at the center of our innovation,” Jan Hoflack, PhD, OPM’s…
In a trial milestone, participants in the third patient group of the ASPIRO Phase 1/2a study (NCT06344026) are now receiving the commercial formulation of ANPD001, Aspen Neuroscience’s cell therapy candidate for Parkinson’s disease. While participants in earlier groups also received ANPD001, the third group is the…
The first European patients in Askbio‘s Phase 2 clinical trial of AB-1005, an experimental gene therapy for Parkinson’s disease, have been randomly assigned to treatment groups. The study, REGENERATE-PD (NCT06285643), has begun randomizing participants at sites in Poland and the U.K. Trial sites in Germany are…
Interactions between receptors for ghrelin, the so-called hunger hormone, and the chemical signaling molecule dopamine may go awry in Parkinson’s disease, potentially leading to chronic constipation — a symptom that the Australian scientists behind this new research called “debilitating” for many people with the condition. To learn more about…
The Parkinson’s Foundation will organize events in 20 U.S. cities this fall as part of Moving Day, a walk to increase awareness of Parkinson’s disease and raise funds for research. “Moving Day is much more than a fundraiser,” John Poma, a member of the foundation’s People with…
The Michael J. Fox Foundation (MJFF) is funding work to develop imaging technology for monitoring toxic proteins in Parkinson’s disease. Xingimaging said it and its partner Synusight Biotech will use the $3.84 million grant to fund studies and work toward clinical application of their compound, 18F-FD4.
A new study suggests that simple, targeted strategies, from using telehealth to standardizing patient referrals, could help more people with Parkinson’s disease get the specialized care they urgently need. With U.S. cases expected to double by 2040, researchers warn that existing healthcare inequities will worsen without immediate action. “Research…
People with metabolic syndrome, a cluster of metabolism-related abnormalities — like a larger waist circumference, high blood sugar, and abnormal blood levels of fatty molecules — may have a higher risk of Parkinson’s disease, according to the findings of a new study by an international team of researchers. Having…
Get regular updates to your inbox.
